Results 21 to 30 of about 338,912 (243)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms

eJHaem, 2022
This report highlights the value of flow cytometry analysis, particularly in the setting of myeloproliferative neoplasms showing features of progression, as neoplastic plasmacytoid dendritic cell (PDC) proliferations may be present, representing either a
Siba El Hussein, Mariko Yabe, Wei Wang, Naveen Pemmaraju, Sanam Loghavi, Fatima Zahra Jelloul, Hong Fang, L. Jeffrey Medeiros, W. Richard Burack, Andrew G. Evans, Jane L. Liesveld, John M. Bennett   +11 more
doaj   +1 more source

Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm

Journal of Clinical Investigation, 2020
Arterial cardiovascular events are the leading cause of death in patients with JAK2V617F myeloproliferative neoplasms (MPNs). However, their mechanisms are poorly understood.
J. Poisson, M. Tanguy, Hortense Davy, F. Camara, Marie-Belle El Mdawar, M. Kheloufi, Tracy Dagher, C. Devue, Juliette Lasselin, A. Plessier, S. Merchant, O. Blanc-Brude, M. Souyri, N. Mougenot, F. Dingli, D. Loew, S. Hatem, C. James, J. Villeval, C. Boulanger, P. Rautou   +20 more
semanticscholar   +1 more source

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values

Haematologica, 2019
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV),
Richard T. Silver, Spencer Krichevsky
doaj   +1 more source

N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm.

Blood Advances, 2020
Thrombosis is a major cause of mortality in patients with myeloproliferative neoplasms (MPNs), though there is currently little to offer patients with MPN beyond aspirin and cytoreductive therapies such as hydroxyurea for primary prevention ...
Brianna M. Craver, Gajalakshmi Ramanathan, Summer Hoang, Xinyue Chang, Laura F Mendez Luque, S. Brooks, H. Lai, Angela G. Fleischman   +7 more
semanticscholar   +1 more source

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation

SAGE Open Medical Case Reports, 2021
The entity myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome is characterized by the coexistence of both myeloproliferative and myelodysplastic features in the bone marrow.
Anette Lodvir Hemsing, Bjørn Tore Gjertsen, Signe Spetalen, Lars Helgeland, Håkon Reikvam   +4 more
doaj   +1 more source

Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Hematology. American Society of Hematology. Education Program, 2020
Myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes are uniquely classified neoplasms occurring in both children and adults.
M. Patnaik, T. Lasho
semanticscholar   +1 more source

Phylogenetic reconstruction of myeloproliferative neoplasm reveals very early origins and lifelong evolution

bioRxiv, 2020
Mutations in cancer-associated genes drive tumour outgrowth. However, the timing of driver mutations and dynamics of clonal expansion that lead to human cancers are largely unknown.
N. Williams, J. J. Lee, L. Moore, E. Baxter, J. Hewinson, K. Dawson, A. Menzies, A. Godfrey, Anthony R. Green, Anthony R. Green, Peter J. Campbell, Peter J. Campbell, J. Nangalia   +12 more
semanticscholar   +1 more source

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

Haematologica, 2011
Within a cohort of 1,915 consecutive patients with myeloproliferative neoplasm followed for a median time of 5.2 years (range 0–33.3), we investigated the occurrence of lymphoid neoplasm with the aim of defining this risk and to investigate the role of ...
Elisa Rumi, Francesco Passamonti, Chiara Elena, Daniela Pietra, Luca Arcaini, Cesare Astori, Silvia Zibellini, Emanuela Boveri, Cristiana Pascutto, Mario Lazzarino   +9 more
doaj   +1 more source

Extracranial carotid artery aneurysm with myeloproliferative neoplastic cell invasion

Journal of Vascular Surgery Cases and Innovative Techniques, 2020
The major causes of rare extracranial carotid artery aneurysms are arteriosclerosis, trauma, and radiation therapy. Here, we describe a patient with an extracranial carotid artery aneurysm caused by a myeloproliferative neoplasm.
Shotaro Ogawa, MD, Masanori Yoshino, MD, PhD, Takayuki Hara, MD, PhD   +2 more
doaj   +1 more source

IL-4 Serum Level Estimation in Myeloproliferative Neoplasm Patients

مجلة مركز بحوث التقنيات الاحيائية, 2022
Back Ground: Myeloproliferative neoplasm (MPN) is a long-term blood disease that has an excess production of mature hematopoietic pluripotent stem cells in the bone marrow. In the early fifties, W.
Ahmed Rushdi Abdullah
doaj   +1 more source